Gynae BT 2017

Swedish randomised trial (1997-2008)

Stage I ‘medium risk ‘ (n=527)

VBT

EBRT+VBT

Vaginal recurrence (crude)

2.7% 5.0% 90%

1.9% 1.5% 89%

Locoregional

Overall Survival

Toxicity Gr 3: GI

0%

2% 0%

vagina 0.8%

➢ Similar QoL results favoring VBT alone

Sorbe et al, IJROBP 2012 + Int J Gynecol Cancer 2012